1. Home
  2. IROH vs CGTX Comparison

IROH vs CGTX Comparison

Compare IROH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROH
  • CGTX
  • Stock Information
  • Founded
  • IROH 2021
  • CGTX 2007
  • Country
  • IROH United States
  • CGTX United States
  • Employees
  • IROH N/A
  • CGTX N/A
  • Industry
  • IROH
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROH
  • CGTX Health Care
  • Exchange
  • IROH Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • IROH 91.2M
  • CGTX 79.3M
  • IPO Year
  • IROH 2023
  • CGTX 2021
  • Fundamental
  • Price
  • IROH $10.32
  • CGTX $0.42
  • Analyst Decision
  • IROH
  • CGTX Buy
  • Analyst Count
  • IROH 0
  • CGTX 6
  • Target Price
  • IROH N/A
  • CGTX $8.00
  • AVG Volume (30 Days)
  • IROH 11.9K
  • CGTX 444.9K
  • Earning Date
  • IROH 01-01-0001
  • CGTX 11-13-2024
  • Dividend Yield
  • IROH N/A
  • CGTX N/A
  • EPS Growth
  • IROH N/A
  • CGTX N/A
  • EPS
  • IROH 0.20
  • CGTX N/A
  • Revenue
  • IROH N/A
  • CGTX N/A
  • Revenue This Year
  • IROH N/A
  • CGTX N/A
  • Revenue Next Year
  • IROH N/A
  • CGTX N/A
  • P/E Ratio
  • IROH $52.68
  • CGTX N/A
  • Revenue Growth
  • IROH N/A
  • CGTX N/A
  • 52 Week Low
  • IROH $9.97
  • CGTX $0.34
  • 52 Week High
  • IROH $11.11
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • IROH N/A
  • CGTX 41.17
  • Support Level
  • IROH N/A
  • CGTX $0.43
  • Resistance Level
  • IROH N/A
  • CGTX $0.48
  • Average True Range (ATR)
  • IROH 0.00
  • CGTX 0.04
  • MACD
  • IROH 0.00
  • CGTX -0.01
  • Stochastic Oscillator
  • IROH 0.00
  • CGTX 7.26

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: